North Star Investment Management’s Meridian Bioscience Inc VIVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-500
Closed -$16.6K 1347
2022
Q4
$16.6K Hold
500
﹤0.01% 768
2022
Q3
$16K Hold
500
﹤0.01% 733
2022
Q2
$15K Hold
500
﹤0.01% 754
2022
Q1
$13K Hold
500
﹤0.01% 830
2021
Q4
$10K Hold
500
﹤0.01% 914
2021
Q3
$10K Hold
500
﹤0.01% 872
2021
Q2
$11K Hold
500
﹤0.01% 844
2021
Q1
$13K Hold
500
﹤0.01% 759
2020
Q4
$9K Hold
500
﹤0.01% 805
2020
Q3
$8K Hold
500
﹤0.01% 789
2020
Q2
$12K Hold
500
﹤0.01% 699
2020
Q1
$4K Buy
+500
New +$4.21K ﹤0.01% 866
2018
Q4
Sell
-52,935
Closed -$789K 1106
2018
Q3
$789K Buy
52,935
+60
+0.1% +$930 0.09% 231
2018
Q2
$841K Hold
52,875
0.1% 225
2018
Q1
$751K Buy
52,875
+975
+2% +$14.4K 0.09% 226
2017
Q4
$727K Sell
51,900
-1,175
-2% -$17.2K 0.09% 221
2017
Q3
$759K Hold
53,075
0.1% 217
2017
Q2
$836K Sell
53,075
-30,000
-36% -$432K 0.11% 196
2017
Q1
$1.15M Buy
83,075
+42,775
+106% +$598K 0.16% 158
2016
Q4
$713K Buy
+40,300
New +$708K 0.11% 197

Other funds holding VIVO

North Star Investment Management's VIVO Position: Q1 2023 in Review

North Star Investment Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 500 shares — an estimated $16.6K sold.

North Star Investment Management first reported a position in VIVO in Q4 2016 and held it in 20 quarters. The position peaked at $1.15M in Q1 2017. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • North Star Investment Management reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • North Star Investment Management sold 500 Meridian Bioscience Inc shares in Q1 2023, an estimated $16.6K.
  • North Star Investment Management first reported a position in Meridian Bioscience Inc in Q4 2016 and held it in 20 quarters.
  • North Star Investment Management's Meridian Bioscience Inc position peaked at $1.15M in Q1 2017.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on North Star Investment Management's 13F filing for Q1 2023, filed 27 Apr 2023.